Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?
Kay F. Macleod
Kay F. Macleod
Published November 22, 2010
Citation Information: J Clin Invest. 2010;120(12):4179-4182. https://doi.org/10.1172/JCI45406.
View: Text | PDF
Commentary

The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?

  • Text
  • PDF
Abstract

The retinoblastoma tumor suppressor gene (RB1; encoding RB) is often cited as a gatekeeper, whose inactivation — direct or indirect — is a rate-limiting step for tumor initiation. However, in this issue of the JCI, Sharma et al. show that RB1 loss is a late event in human prostate cancer that is coincident with the emergence of castrate-resistant metastatic disease. This role for RB1 was linked to both E2F transcription factor 1–driven upregulation of the androgen receptor (AR) and increased recruitment of the AR to target gene promoters. This unexpected function for RB1 in late-stage cancer calls upon us to reassess the significance of RB1 inactivation in other cancers in terms of its timing, function in disease etiology, and relevance for cancer therapy.

Authors

Kay F. Macleod

×

Total citations by year

Year: 2025 2024 2022 2021 2019 2016 2015 2014 2013 2012 2011 Total
Citations: 2 1 1 1 3 2 1 1 1 1 5 19
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (19)

Title and authors Publication Year
Interactions between key genes and pathways in prostate cancer progression and therapy resistance
Wu F, Zhang H, Hao M
Frontiers in Oncology 2025
Defining the Molecular Intricacies of Human Papillomavirus-Associated Tonsillar Carcinoma
Sethi S
Cancer Control : Journal of the Moffitt Cancer Center 2025
In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC
Gregoris F, Minervini G, Tosatto SC
Genes 2024
Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View
Rajabi S, Alix-Panabières C, Alaei AS, Abooshahab R, Shakib H, Ashrafi MR
Cancers 2022
Novel insights in cell cycle dysregulation during prostate cancer progression
S Ben-Salem, VB Venkadakrishnan
Endocrine Related Cancer 2021
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types
WS Chen, M Alshalalfa, SG Zhao, Y Liu, BA Mahal, DA Quigley, T Wei, E Davicioni, TR Rebbeck, PW Kantoff, CA Maher, KE Knudsen, EJ Small, PL Nguyen, FY Feng
Clinical cancer research 2019
The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression
H Liu, Z Wu, H Zhou, W Cai, X Li, J Hu, L Gao, T Feng, L Wang, X Peng, M Qi, L liu, B Han
Neoplasia (New York, N.Y.) 2019
Computational analyses for cancer biology based on exhaustive experimental backgrounds.
Koseki J, Konno M, Ishii H
2019
Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status
P Leidinger, M Hart, C Backes, S Rheinheimer, B Keck, B Wullich, A Keller, E Meese
Tumor Biology 2016
The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells
MP Labrecque, MK Takhar, R Nason, S Santacruz, KJ Tam, S Massah, A Haegert, RH Bell, M Altamirano-Dimas, CC Collins, FJ Lee, GG Prefontaine, ME Cox, TV Beischlag
Oncotarget 2016
Das neuroendokrine Prostatakarzinom
A Kretschmer, C Wittekind, CG Stief, C Gratzke
Der Urologe, Ausgabe A 2015
Molecular pathways and targets in prostate cancer
Shtivelman E, Beer TM, Evans CP
Oncotarget 2014
Mitochondrial Dysfunction in Cancer
ML Boland, AH Chourasia, KF Macleod
Frontiers in Oncology 2013
Estimating the order of mutations during tumorigenesis from tumor genome sequencing data
A Youn, R Simon
Bioinformatics 2012
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer
A Aparicio, RB Den, KE Knudsen
Nature Reviews Urology 2011
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome
BT Spike, GM Wahl
Genes & cancer 2011
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
KE Knudsen, WK Kelly
Expert Review of Endocrinology & Metabolism 2011
Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells
SC Chiu, MJ Wang, HH Yang, SP Chen, SY Huang, YL Chen, SZ Lin, HJ Harn, CY Pang
BMC Cancer 2011
Epidemiology and Rb1 gene of retinoblastoma
J Yun, Y Li, CT Xu, BR Pan
International Journal of Ophthalmology 2011

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts